Cargando…

Counteracting oxidative phosphorylation-mediated resistance of melanomas to MAPK pathway inhibition

Mitochondrial oxidative phosphorylation (OxPhos) induces resistance to MAPK pathway inhibitors in melanoma. However, therapeutic targeting of mitochondria is challenging. In a recent study, we showed that inhibition of mTOR kinase activity resensitized resistant melanomas by indirectly inhibiting Ox...

Descripción completa

Detalles Bibliográficos
Autores principales:	McQuade, Jennifer L, Vashisht Gopal, Yn
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2015
Materias:	Author's Views
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4905309/ https://www.ncbi.nlm.nih.gov/pubmed/27308473 http://dx.doi.org/10.4161/23723556.2014.991610

Ejemplares similares

EGFR-mediated tumor immunoescape: The imbalance between phosphorylated STAT1 and phosphorylated STAT3
por: Concha-Benavente, Fernando, et al.
Publicado: (2013)

Sugars boost exhausted tumor-infiltrating lymphocytes by counteracting immunosuppressive activities of galectins
por: Gordon-Alonso, Monica, et al.
Publicado: (2014)

MAPK signaling regulates the efficacy of chemoimmunotherapy
por: Ghiringhelli, François
Publicado: (2022)

Inhibition of BRAF and BRAF+MEK drives a metastatic switch in melanoma
por: Smalley, Keiran SM, et al.
Publicado: (2015)

BRAF-targeted therapy alters the functions of intratumoral CD4(+) T cells to inhibit melanoma progression
por: Ho, Ping-Chih, et al.
Publicado: (2014)

Immune mediated mechanisms of melanocyte destruction: Paving the way for efficient immunotherapeutic strategies against melanoma
por: Speeckaert, Reinhart, et al.
Publicado: (2012)

Combining checkpoint inhibitors and BRAF-targeted agents against metastatic melanoma
por: Cooper, Zachary A., et al.
Publicado: (2013)

Melanoma immunoediting by NK cells
por: Balsamo, Mirna, et al.
Publicado: (2012)

Melanoma metastases caught in the AKT
por: Kircher, David A., et al.
Publicado: (2016)

The PHD motif of Map3k1 activates cytokine-dependent MAPK signaling
por: Gallagher, Ewen, et al.
Publicado: (2015)

Clinical, molecular, metabolic, and immune features associated with oxidative phosphorylation in melanoma brain metastases
por: Fischer, Grant M, et al.
Publicado: (2021)

Evidence of synergy with combined BRAF-targeted therapy and immune checkpoint blockade for metastatic melanoma
por: Cooper, Zachary A, et al.
Publicado: (2014)

Monocytic myeloid-derived suppressor cells in advanced melanoma patients: Indirect impact on prognosis through inhibition of tumor-specific T-cell responses?
por: Martens, Alexander, et al.
Publicado: (2014)

Targeting mutagenesis in B cells: Phosphorylation goes beyond AID association
por: Mu, Yunxiang, et al.
Publicado: (2018)

BRAF-targeted therapy and immune responses to melanoma
por: Ngiow, Shin Foong, et al.
Publicado: (2013)

How melanoma cells inactivate NK cells
por: Pietra, Gabriella, et al.
Publicado: (2012)

Disseminating melanoma cells surf on calcium waves
por: Sun, Jianwei, et al.
Publicado: (2015)

The heat shock protein-CD91 pathway mediates tumor immunosurveillance
por: Zhou, Yu Jerry, et al.
Publicado: (2014)

Itraconazole perturbs colorectal cancer dormancy through SUFU-mediated WNT inhibition
por: Popova, Semiramis A., et al.
Publicado: (2018)

Is there a future for adoptive cell transfer in melanoma patients?
por: Besser, Michal J
Publicado: (2013)

The antigen specific composition of melanoma tumor infiltrating lymphocytes?
por: Hadrup, Sine Reker
Publicado: (2012)

Combined targeted therapy and immunotherapy in the treatment of advanced melanoma
por: Wilmott, James S., et al.
Publicado: (2012)

Lymphoid neogenesis in melanoma: What does it tell us?
por: van Baren, Nicolas, et al.
Publicado: (2013)

Ser(784) phosphorylation: a clinically relevant enhancer of VCP function in the DNA damage response
por: Shao, Jieya
Publicado: (2020)

Engineering hematopoietic stem cells to create melanoma specific CTL
por: Vatakis, Dimitrios
Publicado: (2012)

Forging a link between oncogenic signaling and immunosuppression in melanoma
por: Khalili, Jahan S., et al.
Publicado: (2013)

Neuropilin 1 guides regulatory T cells into VEGF-producing melanoma
por: Hansen, Wiebke
Publicado: (2013)

NRAS-driven melanoma: A RAF can hide another
por: Druillennec, Sabine, et al.
Publicado: (2017)

β-catenin-mediated inhibition of cross-priming: A new mechanism for tumors to evade immunosurveillance
por: Fu, Chunmei, et al.
Publicado: (2013)

New strategies for melanoma immunotherapy: How to overcome immunosuppression in the tumor microenvironment
por: Umansky, Viktor
Publicado: (2012)

Immune response markers in sentinel nodes may predict melanoma progression
por: Rodolfo, Monica, et al.
Publicado: (2014)

Identification of new prognostic biomarkers for Stage III metastatic melanoma patients
por: Kakavand, Hojabr, et al.
Publicado: (2013)

Ipilimumab in a Phase II trial of melanoma patients with brain metastases
por: Margolin, Kim
Publicado: (2012)

Enhancing anti-melanoma immunity by electrochemotherapy and in vivo dendritic-cell activation
por: Gerlini, Gianni, et al.
Publicado: (2012)

Melanoma hijacks plasmacytoid dendritic cells to promote its own progression
por: Aspord, Caroline, et al.
Publicado: (2014)

Ferroptosis resistance mediated by exosomal release of iron
por: Brown, Caitlin W., et al.
Publicado: (2020)

Resistance to kinase inhibition through shortened target engagement
por: Rangwala, Aziz M., et al.
Publicado: (2022)

Immunotargeting of tumor subpopulations in melanoma patients: A paradigm shift in therapy approaches
por: Maurer, Margarita, et al.
Publicado: (2012)

A path from melanocyte stem cells to cutaneous melanoma illuminated by UVB
por: Moon, Hyeongsun, et al.
Publicado: (2018)

“Suffocating” tumors by blocking adaptation to hypoxia: a new headway in melanoma immunotherapy
por: Janji, Bassam, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_039qd2ogjo07nnilsakg59drdk